Form 4: Director Mark Frohlich Receives Rigel Stock Grant

Rigel Pharmaceuticals director Mark W. Frohlich was granted 5,750 restricted stock units as part of his board compensation.

Summary

• Director Mark W. Frohlich acquired 5,750 shares of Rigel Pharmaceuticals (RIGL) common stock.
• The acquisition occurred on May 15, 2026, via the vesting of a Restricted Stock Unit (RSU) award.
• The shares were granted at a price of $0 per share as part of equity-based compensation.
• Following this transaction, the director's total beneficial ownership of common stock increased to 7,000 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation rather than a strategic shift or market-moving event.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Increase in direct equity stake held by a member of the Board of Directors.

Negatives

• None identified; this is a standard director compensation event.

Risks

• Vesting of the RSU award is contingent upon the reporting person's continuous service on the Board of Directors until the date prior to the next Annual Meeting.

Future Outlook

The RSU award is scheduled to fully vest on the date prior to the company's next Annual Meeting, provided the director maintains continuous service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are a standard corporate governance practice in the biotechnology sector to ensure board members have a vested interest in long-term company performance.

Comparison to Industry Standards

• The grant of RSUs to directors is consistent with standard compensation packages for board members at mid-cap and small-cap pharmaceutical companies.
• The vesting schedule tied to the annual meeting cycle is a common practice among NASDAQ-listed life sciences firms.

Stakeholder Impact

• Minimal impact on shareholders as this represents standard director compensation.

Next Steps

• Vesting of the 5,750 RSUs on the day prior to the next Annual Meeting.

Key Dates

Keywords

Rigel Pharmaceuticals, RIGL, Form 4, Insider Trading, Director Compensation, Restricted Stock Units